Haemonetics (NYSE:HAE) Issues Earnings Results, Misses Estimates By $0.01 EPS

Haemonetics (NYSE:HAE) released its quarterly earnings data on Thursday. The medical instruments supplier reported $1.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.03 by ($0.01), Briefing.com reports. The company had revenue of $336.17 million for the quarter, compared to analyst estimates of $335.08 million. Haemonetics had a net margin of 8.98% and a return on equity of 22.25%. The company’s revenue for the quarter was up 8.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.05 EPS. Haemonetics updated its FY25 guidance to $4.45 to $4.75 EPS and its FY 2025 guidance to 4.450-4.750 EPS.

Haemonetics Price Performance

Shares of HAE traded up $0.60 during midday trading on Friday, reaching $77.03. The stock had a trading volume of 848,252 shares, compared to its average volume of 525,351. The company has a debt-to-equity ratio of 0.83, a current ratio of 2.56 and a quick ratio of 1.50. The company has a market capitalization of $3.92 billion, a P/E ratio of 33.64, a P/E/G ratio of 1.64 and a beta of 0.29. The firm’s 50 day moving average price is $86.50 and its 200-day moving average price is $84.13. Haemonetics has a 52 week low of $70.74 and a 52 week high of $97.97.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. Needham & Company LLC raised Haemonetics from a “hold” rating to a “buy” rating and set a $112.00 target price on the stock in a research note on Wednesday, June 12th. Barrington Research lifted their target price on Haemonetics from $107.00 to $108.00 and gave the company an “outperform” rating in a research note on Friday. Finally, JMP Securities lifted their target price on Haemonetics from $115.00 to $125.00 and gave the company a “market outperform” rating in a research note on Friday, May 10th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $109.75.

Insider Buying and Selling

In related news, insider Stewart W. Strong sold 8,857 shares of Haemonetics stock in a transaction on Wednesday, May 29th. The stock was sold at an average price of $87.53, for a total value of $775,253.21. Following the transaction, the insider now directly owns 18,196 shares in the company, valued at approximately $1,592,695.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, insider Stewart W. Strong sold 686 shares of Haemonetics stock in a transaction on Monday, May 20th. The stock was sold at an average price of $95.11, for a total value of $65,245.46. Following the transaction, the insider now directly owns 18,196 shares in the company, valued at approximately $1,730,621.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Stewart W. Strong sold 8,857 shares of Haemonetics stock in a transaction on Wednesday, May 29th. The stock was sold at an average price of $87.53, for a total value of $775,253.21. Following the completion of the transaction, the insider now owns 18,196 shares in the company, valued at $1,592,695.88. The disclosure for this sale can be found here. Insiders have sold 31,523 shares of company stock worth $2,812,120 in the last three months. 1.80% of the stock is currently owned by insiders.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.